William Blair Investment Management LLC reduced its position in shares of Chemed Co. (NYSE:CHE – Free Report) by 5.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 530,809 shares of the company’s stock after selling 29,362 shares during the […]
Swiss multinational healthcare company, Roche, has terminated its worldwide license and collaboration agreement with Repare Therapeutics despite the company earning a $40 million milestone payment from Roche.
LONDON/FRANKFURT (Reuters) -Roche forecast a pick up in sales growth this year as it overcomes a slump in demand for its COVID-19 products and a decline in sales of a trio of established cancer drugs abates. Sales in 2023 rose 1% to 58.7 billion Swiss francs ($68 billion), slightly below analysts' average estimate of closer to 60 billion francs, according to LSEG data. CEO Thomas Schinecker told reporters it was a "significant achievement" that the company increased sales despite the sharp drop in demand for its COVID therapy and diagnostics kits.
Swiss pharmaceutical company Roche announced net income was down but it expects mid single-digit sales increase for 2024. Roche reported that its International Financial Reporting Standards (IFRS) net income for fiscal year 2023 declined about 9% to 12.36 billion Swiss francs from 13.53 billion francs last year. But IFRS net income increased by 7% at constant exchange rates (CER) due to the increase in operating profit and lower income tax expenses. Core earnings per share was 18.57 francs down